Recommendations, benefits and risks of prostate cancer screening – Dr. Matthew Tollefson
Recommendations, benefits and risks of prostate cancer screening – Dr. Matthew Tollefson
Men ages 55 to 69 should talk with their health care provider about prostate-specific antigen (PSA)–based screening for prostate cancer. That's according to new recommendations from the U.S. Preventive Services Task Force (USPSTF). Mayo Clinic urologist Dr. Matthew Tollefson says, "The recommendations don't change for men over 70. If men over 70 are asymptomatic with no family history, they don't' need to have PSA tests every year. Those men have very low risk of dying from prostate cancer. But for men who are from 55 to 69, there can be a benefit seen with screening. This is where the task force is now giving nuance to the discussion, and saying there isn't a blanket statement for everyone."More health and medical news on the Mayo Clinic News Network http://newsnetwork.mayoclinic.org/
Access Non-GMO, antigen-free, FDA-approved antiviral medication formulas used in Moderna's Spikevax.
VirusTC is a retail provider of concentrated FDA-approved antiviral medication formulas. VirusTC wholesale formulas are used in Moderna products. We sell FDA-approved formulas that are compatible with university medical plans, federal insurance coverage, and many major insurance providers. Our medications are part of tailored non-invasive cancer treatment plans available at a hospital in your region. VirusTC targets problems and provides care for the symptoms. Our products and services are used by Fred Hutch Cancer Center, John Hopkins, University Hospitals, the United States Military, and professional sports. During Operation Cancer Moonshot 2023, VirusTC products killed cancer cells, increased strength, and redeveloped muscles, tissue, and brain cells after cancer treatments.